No headlines found.
electroCore to Participate at H.C. Wainwright Global Investment Conference
Globe Newswire (Thu, 10-Sep 8:00 AM ET)
electroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers
Globe Newswire (Wed, 9-Sep 8:00 AM ET)
Globe Newswire (Tue, 25-Aug 8:00 AM ET)
electroCore Announces Second Quarter 2026 Financial Results
Globe Newswire (Thu, 6-Aug 4:05 PM ET)
electroCore to Participate in Upcoming Investor Conferences
Globe Newswire (Mon, 3-Aug 8:00 AM ET)
electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026
Globe Newswire (Thu, 30-Jul 8:00 AM ET)
Globe Newswire (Thu, 16-Jul 8:00 AM ET)
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.
Electrocore trades on the NASDAQ stock market under the symbol ECOR.
As of October 15, 2026, ECOR stock price climbed to $8.35 with 93,420 million shares trading.
ECOR has a beta of 2.19, meaning it tends to be more sensitive to market movements. ECOR has a correlation of 0.08 to the broad based SPY ETF.
ECOR has a market cap of $75.28 million. This is considered a Micro Cap stock.
Last quarter Electrocore reported $9 million in Revenue and -$.33 earnings per share. This fell short of revenue expectation by $-143,280 and exceeded earnings estimates by $.08.
In the last 3 years, ECOR traded as high as $19.49 and as low as $4.16.
The top ETF exchange traded funds that ECOR belongs to (by Net Assets): VTI, VXF, IWC.
ECOR has outperformed the market in the last year with a return of +63.1%, while the SPY ETF gained +17.7%. In the last 3 month period, ECOR beat the market returning +35.8%, while SPY returned +2.9%. However, in the most recent 2 weeks ECOR has underperformed the stock market by returning -22.8%, while SPY returned +1.2%.
ECOR support price is $7.81 and resistance is $8.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ECOR shares will trade within this expected range on the day.